Skip to content
Eternal Peptides AUS Research supply Cart 1
TB-500 (5mg) – TB05
TB05 / 10 × 5mg / COA ×4 BTB
Record TB05 BPC-157 & TB-500

TB-500

$445.50
Box of 10 vials · 5mg per vial
SKU
TB05
Presentation
10 vials × 5mg
Research area
Certificates
All four tests on file
Availability
In stock
Assay matrix 4 / 4

Select a filled cell to read the certificate.

Monograph

TB-500 (5mg) — Research Peptide

TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein expressed ubiquitously across mammalian cell types. Unlike the full Tβ4 protein, the TB-500 fragment retains the primary actin-binding domain responsible for Tβ4’s documented biological activities, making it the standard research form used in published studies investigating Thymosin Beta-4 biology.

Biology of Thymosin Beta-4

Thymosin Beta-4 was first isolated from thymic tissue in the 1960s and initially characterised as a thymic hormone. Subsequent research established it as a ubiquitous intracellular protein whose primary function is G-actin sequestration — binding to monomeric actin and preventing its polymerisation into F-actin filaments. This regulatory role in actin dynamics has far-reaching consequences for cell motility, as directed cell migration depends on controlled actin polymerisation at the leading edge of migrating cells.

Research Applications

Published research has investigated TB-500/Tβ4 across several biological contexts:

  • Wound healing: Tβ4 promotes dermal fibroblast migration and wound closure via ILK (integrin-linked kinase) activation. Goldstein et al. demonstrated accelerated wound repair in rodent models with Tβ4 administration.
  • Cardiac research: A landmark 2004 Nature study (Bock-Marquette et al.) demonstrated Tβ4 activates epicardial progenitor cells and promotes cardiomyocyte survival following myocardial injury models — a finding that generated significant follow-on cardiac regeneration research.
  • Skeletal muscle: Tβ4 promotes satellite cell differentiation and muscle fibre regeneration following injury in rodent models.
  • Corneal and ocular: Phase 2 clinical trials investigated Tβ4 in dry eye and neurotrophic keratopathy — among the few peptides with human clinical data in this domain.

Product Specifications

  • Peptide: TB-500 (Thymosin Beta-4 active fragment)
  • Dose: 5mg per vial
  • Format: Lyophilised powder, bulk box of 10 vials
  • Purity: ≥98% verified by Janoshik HPLC analysis
  • Testing: Purity, sterility, endotoxin, heavy metals — COA available
  • Storage: -20°C lyophilised. Stable 24 months.

For laboratory research use only. Not for human therapeutic use.

Same research area

BPC-157 & TB-500

View all 6